title: Anti-tumor effect of adipose tissue derived-mesenchymal stem cells expressing interferon-β and treatment with cisplatin in a xenograft mouse model for canine melanoma.
abstract: Adipose tissue-derived mesenchymal stem cells (AT-MSCs) are attractive cell-therapy vehicles for the delivery of anti-tumor molecules into the tumor microenvironment. The innate tropism of AT-MSCs for tumors has important implications for effective cellular delivery of anti-tumor molecules, including cytokines, interferon, and pro-drugs. The present study was designed to determine the possibility that the combination of stem cell-based gene therapy with low-dose cisplatin would improve therapeutic efficacy against canine melanoma. The IFN-β transduced canine AT-MSCs (cAT-MSC-IFN-β) inhibited the growth of LMeC canine melanoma cells in direct and indirect in vitro co-culture systems. In animal experiments using BALB/c nude mouse xenografts, which developed by injecting LMeC cells, the combination treatment of cAT-MSC-IFN-β and low-dose cisplatin significantly reduced tumor volume compared with the other treatment groups. Fluorescent microscopic analysis with a TUNEL (terminal deoxynucleotidyl transferase-mediated nick-end labeling) assay of tumor section provided evidence for homing of cAT-MSC-IFN-β to the tumor site and revealed that the combination treatment of cAT-MSC-IFN-β with low-dose cisplatin induced high levels of cell apoptosis. These findings may prove useful in further explorations of the application of these combined approaches to the treatment of malignant melanoma and other tumors.
authors.affiliation: Department of Internal Medicine, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea.
authors.forename: Jin ok
authors.initials: Jo
authors.lastname: Ahn
authors.forename: Hee woo
authors.initials: Hw
authors.lastname: Lee
authors.forename: Kyoung won
authors.initials: Kw
authors.lastname: Seo
authors.forename: Sung keun
authors.initials: Sk
authors.lastname: Kang
authors.forename: Jeong chan
authors.initials: Jc
authors.lastname: Ra
authors.forename: Hwa young
authors.initials: Hy
authors.lastname: Youn
mesh_terms: D000273:Adipose Tissue / Q000166:cytology; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002453:Cell Cycle; D045744:Cell Line, Tumor; D002465:Cell Movement; D002945:Cisplatin / Q000008:administration & dosage*; D018920:Coculture Techniques; D004285:Dogs; D005260:Female; D015316:Genetic Therapy / Q000379:methods; D016899:Interferon-beta / Q000378:metabolism*; D016086:Lentivirus / Q000235:genetics; D008545:Melanoma / Q000628:therapy*; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000166:cytology; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D013234:Stem Cells / Q000166:cytology; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D016899:Interferon-beta; D002945:Cisplatin
references.citation: Curr Stem Cell Res Ther. 2008 Jan;3(1):32-42
references.pmid: 18220921
references.citation: J Exp Med. 2006 May 15;203(5):1235-47
references.pmid: 16636132
references.citation: Tissue Eng Part A. 2008 Jun;14(6):1007-15
references.pmid: 19230125
references.citation: Hematol Oncol Clin North Am. 2006 Jun;20(3):751-66
references.pmid: 16762733
references.citation: Cancer Gene Ther. 2007 Oct;14(10):828-35
references.pmid: 17599089
references.citation: CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33
references.pmid: 10735013
references.citation: Cancer Res. 2002 Jul 1;62(13):3603-8
references.pmid: 12097260
references.citation: J Cancer Res Clin Oncol. 1995;121(2):84-8
references.pmid: 7883780
references.citation: Cytotherapy. 2003;5(5):362-9
references.pmid: 14578098
references.citation: PLoS One. 2009 Jul 17;4(7):e6278
references.pmid: 19609435
references.citation: Melanoma Res. 1995 Oct;5(5):295-301
references.pmid: 8541719
references.citation: Cancer Lett. 2009 Jul 18;280(1):31-7
references.pmid: 19285791
references.citation: Clin Dermatol. 2004 May-Jun;22(3):251-65
references.pmid: 15262312
references.citation: Gene Ther. 2008 Nov;15(21):1446-53
references.pmid: 18596829
references.citation: Cytotherapy. 2010 Sep;12(5):615-25
references.pmid: 20230221
references.citation: Stem Cells. 2006 May;24(5):1294-301
references.pmid: 16410387
references.citation: Clin Cancer Res. 2004 Feb 15;10(4):1535-44
references.pmid: 14977858
references.citation: J Interferon Cytokine Res. 1996 Apr;16(4):275-81
references.pmid: 9162520
references.citation: Clin Cancer Res. 2006 Sep 15;12(18):5550-6
references.pmid: 17000692
references.citation: Cancer Res. 1996 May 1;56(9):2191-8
references.pmid: 8616871
references.citation: Ann Surg Oncol. 2003 Dec;10(10):1184-90
references.pmid: 14654475
references.citation: Stem Cells. 2011 Jan;29(1):11-9
references.pmid: 21280155
references.citation: J Am Vet Med Assoc. 2001 May 1;218(9):1444-8
references.pmid: 11345308
references.citation: J Clin Oncol. 1984 Apr;2(4):336-52
references.pmid: 6323641
references.citation: Cancer Lett. 2009 Aug 18;281(1):32-41
references.pmid: 19342158
references.citation: J Natl Cancer Inst. 2004 Nov 3;96(21):1593-603
references.pmid: 15523088
references.citation: Apoptosis. 2003 Jun;8(3):237-49
references.pmid: 12766484
references.citation: Ann Intern Med. 1984 May;100(5):704-13
references.pmid: 6370067
references.citation: J Natl Cancer Inst. 1999 Apr 21;91(8):675-90
references.pmid: 10218505
references.citation: Am J Physiol Cell Physiol. 2001 Dec;281(6):C1812-8
references.pmid: 11698239
references.citation: J Dermatol. 1995 Sep;22(9):631-6
references.pmid: 8537547
references.citation: Cancer Res. 2005 Apr 15;65(8):3307-18
references.pmid: 15833864
references.citation: Stem Cells. 2007 Apr;25(4):818-27
references.pmid: 17420225
references.citation: Anticancer Res. 1995 May-Jun;15(3):923-9
references.pmid: 7645983
references.citation: Cancer Lett. 2008 Sep 28;269(1):67-77
references.pmid: 18571836
references.citation: J Vet Med Sci. 2004 Nov;66(11):1437-40
references.pmid: 15585963
references.citation: Prostate. 2011 May;71(6):615-25
references.pmid: 20957670
references.citation: J Autoimmun. 2008 May;30(3):121-7
references.pmid: 18249090
references.citation: J Vet Intern Med. 2003 Jan-Feb;17(1):96-101
references.pmid: 12564733
references.citation: Oncologist. 2001;6(1):34-55
references.pmid: 11161227
references.citation: Nature. 1978 Aug 24;274(5673):798-800
references.pmid: 683317
references.citation: Clin Cancer Res. 2001 Jun;7(6):1821-31
references.pmid: 11410525
references.citation: Exp Hematol. 2005 Nov;33(11):1402-16
references.pmid: 16263424
references.citation: Cancer Treat Rev. 2013 Apr;39(2):180-8
references.pmid: 22494966
references.citation: PLoS One. 2010 Jun 16;5(6):e11140
references.pmid: 20585401
references.citation: J Am Vet Med Assoc. 1994 Jan 15;204(2):229-36
references.pmid: 8144382
references.citation: Breast Cancer Res Treat. 2012 Feb;132(1):153-64
references.pmid: 21584665
references.citation: Expert Opin Ther Targets. 2012 Jul;16(7):689-705
references.pmid: 22620498
references.citation: CA Cancer J Clin. 2000 Jul-Aug;50(4):215-36; quiz 237-40
references.pmid: 10986965
references.citation: J Vet Intern Med. 1999 May-Jun;13(3):163-74
references.pmid: 10357103
references.citation: Cytotherapy. 2011 Sep;13(8):944-55
references.pmid: 21846298